Cardiac Monitors in Oklahoma

MediReport is a cardiovascular information system (CVIS) and clinical software company specializing in unified workflow management and structured data solutions for interventional cardiology. The company develops MediReport 360™, a vendor-neutral, interoperable platform that integrates pre-, intra-, and post-procedure clinical documentation, reporting, and data management across hospitals, ambulatory surgery centers (ASCs), office-based labs (OBLs), and management services organizations (MSOs). The platform provides real-time structured reporting at the point of care, eliminates data silos, and delivers actionable insights for registries, research, analytics, and real-world studies. MediReport 360™ unifies cath lab workflows including scheduling, procedure and physician reporting, CPT code optimization, inventory management, and operational analytics. The solution is designed for rapid implementation and remote accessibility with an intuitive user interface. The company was founded by two interventional cardiologists and has 30+ years of combined clinical and IT expertise. MediReport serves 400+ healthcare organizations across 40+ countries and recently announced a strategic partnership with Philips to deliver end-to-end cardiovascular intelligence workflows to echo labs. The platform emphasizes data integrity, interoperability with the broader healthcare ecosystem, and efficiency gains through workflow consolidation and complexity reduction.

Acarix AS is a cardiac diagnostics company specializing in point-of-care acoustic-based diagnostic solutions for early coronary artery disease (CAD) assessment. The company's flagship product, CADScor® System, uses highly sensitive acoustic technology and advanced computational processing to analyze coronary blood flow and calculate patient-specific CAD risk scores. The system provides non-invasive, radiation-free risk stratification for patients presenting with chest pain or shortness of breath, with demonstrated negative predictive value of at least 96%. CADScor® System has been deployed in over 60,000 patient assessments since 2017 and is supported by 15+ years of research and development covered by 45 patents. The technology has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD and is CE-marked in accordance with EU MDR 2017/745. Clinical evidence from multiple published studies involving over 6,000 patients demonstrates the system's diagnostic performance and utility compared to standard stress testing. The platform enables immediate risk stratification at point of care, potentially reducing unnecessary advanced diagnostic procedures in up to 40% of patients. Acarix targets healthcare professionals and facilities seeking accessible, cost-effective cardiac risk assessment tools that can be deployed regardless of geographical location or socioeconomic constraints.